-
Mashup Score: 9
AbstractAims. Patients often require combination therapies to achieve LDL cholesterol (LDL-C) targets for the primary prevention of atherosclerotic cardiovascul
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 8
Twice-yearly inclisiran provided sustained reductions in LDL cholesterol and PCSK9 concentrations and was well tolerated over 4 years in the extension study. This is the first prospective long-term study to assess repeat hepatic exposure to inclisiran.
Categories: Endocrinology, Latest HeadlinesTweet-
Long-term efficacy and safety of #inclisiran in patients with high #cardiovascular risk and elevated LDL #cholesterol (#ORION-3): results from the 4-year open-label extension of the ORION-1 trial https://t.co/uwxyZyHRYc #OpenAccess
-
-
Mashup Score: 6Les dernières données sur les dyslipidémies - 1 year(s) ago
Les bénéfices sur les événements ischémiques augmentent au cours du temps car le temps d’exposition aux traitements est fondamental avec une réduction de la mortalité cardiovasculaire lors du suivi prolongé des patients. Les études avec les iPCSK9 qui sont des anticorps monoclonaux 100 % humanisés ont confirmé l’excellente tolérance des taux très bas de LDL-C (moyenne des LDL-C autour de 30…
Source: Cardiologie PratiqueCategories: Cardiologists, Latest HeadlinesTweet-
Last data on dyslipidemia at @CNCFCardio congress https://t.co/FlP2GjPPoh #LLT #lipids #LDL #PCSK9i #inclisiran
-
-
Mashup Score: 3
Twice-yearly inclisiran provided sustained reductions in LDL cholesterol and PCSK9 concentrations and was well tolerated over 4 years in the extension study. This is the first prospective long-term study to assess repeat hepatic exposure to inclisiran.
Categories: Endocrinology, Latest HeadlinesTweet-
In the February Issue: Long-term efficacy and safety of #inclisiran in patients with high #cardiovascular risk and elevated LDL #cholesterol (#ORION-3): results from the 4-year open-label extension of the ORION-1 trial https://t.co/uwxyZyIpNK #PCSK9 inhibitor #OpenAccess
-
-
Mashup Score: 0
Twice-yearly inclisiran provided sustained reductions in LDL cholesterol and PCSK9 concentrations and was well tolerated over 4 years in the extension study. This is the first prospective long-term study to assess repeat hepatic exposure to inclisiran.
Categories: Endocrinology, Latest HeadlinesTweet-
In the February Issue: Long-term efficacy and safety of #inclisiran in patients with high #cardiovascular risk and elevated LDL #cholesterol (#ORION-3): results from the 4-year open-label extension of the ORION-1 trial https://t.co/uwxyZyIpNK #OpenAccess
-
-
Mashup Score: 0ORION-3: delivering lipid lowering treatment for longer - 1 year(s) ago
The importance of LDL cholesterol in atherosclerotic cardiovascular disease (ASCVD) is highlighted by countless studies establishing its role in disease causality and clinical trials showing a direct association between lowering LDL cholesterol and reductions in cardiovascular risk. Although treatment guidelines have increasingly emphasised the importance of lipid lowering in cardiovascular…
Categories: Endocrinology, Latest HeadlinesTweet-
Stephen J Nicholls comments on: ORION-3: delivering #lipid lowering treatment for longer https://t.co/OxmWqWEWJT #inclisiran #FREE to read with registration (also FREE)
-
-
Mashup Score: 5
Which patients at risk of cardiovascular disease might benefit the most from inclisiran? Polish experts’ opinion. The compromise between EBM and possibilities in healthcare More details Hide details 1 Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Lodz, Poland 2 Department of…
Source: www.archivesofmedicalscience.comCategories: Cardiologists, Latest HeadlinesTweet-
https://t.co/KrssIRtOCU #Inclisiran #LLT
-
-
Mashup Score: 2
Twice-yearly inclisiran provided sustained reductions in LDL cholesterol and PCSK9 concentrations and was well tolerated over 4 years in the extension study. This is the first prospective long-term study to assess repeat hepatic exposure to inclisiran.
Categories: Endocrinology, Latest HeadlinesTweet-
Long-term efficacy and safety of #inclisiran in patients with high #cardiovascular risk and elevated LDL #cholesterol (#ORION-3): results from the 4-year open-label extension of the ORION-1 trial https://t.co/uwxyZyHRYc #OpenAccess
-
-
Mashup Score: 0ORION-3: delivering lipid lowering treatment for longer - 1 year(s) ago
The importance of LDL cholesterol in atherosclerotic cardiovascular disease (ASCVD) is highlighted by countless studies establishing its role in disease causality and clinical trials showing a direct association between lowering LDL cholesterol and reductions in cardiovascular risk. Although treatment guidelines have increasingly emphasised the importance of lipid lowering in cardiovascular…
Categories: Endocrinology, Latest HeadlinesTweet-
Also read the Linked Comment: #ORION-3: delivering #lipid lowering treatment for longer https://t.co/OxmWqWEoUl #inclisiran
-
-
Mashup Score: 33
Twice-yearly inclisiran provided sustained reductions in LDL cholesterol and PCSK9 concentrations and was well tolerated over 4 years in the extension study. This is the first prospective long-term study to assess repeat hepatic exposure to inclisiran.
Categories: Cardiologists, Latest HeadlinesTweet-
Long-term efficacy and safety of #inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year #OLE of the ORION-1 trial. https://t.co/dz9mSLTNhB
-
#inclisiran https://t.co/KnwCZr13fn RT of @MaxGnecchi